Pioneering sustained back pain treatment
About SpineThera
SpineThera is a clinical-stage company working to improve the lives of patients suffering from radicular leg pain (sciatica). SpineThera’s lead asset, SX600, uses the Faros™ technology to provide months-long sustained-release of dexamethasone from a single epidural injection.
About SpineThera
SpineThera is a clinical-stage company working to improve the lives of patients
suffering from radicular leg pain (sciatica). SpineThera’s lead asset, SX600, uses the
Faros™ technology to provide months-long sustained-release of dexamethasone from a single epidural injection.
Challenge in Back Pain
Back pain, including lumbar radicular pain, is the most common cause of disability within the United States and globally, and is the most expensive indication in healthcare. Currently there is no FDA-approved drug for epidural injection to treat lumbar radicular pain (sciatica).
This debilitating condition commonly requires repeated epidural corticosteroid injections to achieve and maintain adequate pain relief.
Solution
The company’s lead asset, SX600, is a novel formulation of Dexamethasone using Faros™ technology being developed for lumbar radicular pain (sciatica). Clinically meaningful and durable reduction in lumbar radicular pain from a single epidural injection of SX600 in a Phase 2 trial highlighted the potential for best-in-class efficacy.
Challenge in Back Pain
Back pain, including lumbar radicular pain, is the most common cause of disability within the United States and globally, and is the most expensive indication in healthcare. Currently, there is no FDA-approved drug for epidural injection to treat lumbar radicular pain (sciatica). This debilitating condition commonly requires repeated epidural corticosteroid injections to achieve and maintain adequate pain relief.
Solution
The company’s lead asset, SX600, is a novel formulation of dexamethasone using Faros™ technology being developed for lumbar radicular pain (sciatica). Clinically meaningful and durable reduction in lumbar radicular pain from a single epidural injection of SX600 in a Phase 2 trial highlighted the potential for best-in-class efficacy.
.jpg)
Pre-clinical
IND-enabling
Ph1
Ph2 *
SX600
awdawd_edited.jpg)
Ph3 *
*Additional non-rodent tox study required before opening an IND to complete Phase 2 studies.
Pipeline
Pre-clinical
IND-enabling
Ph1
Ph2 *
SX600
Ph3
*Additional non-rodent tox study required before opening an IND to complete Phase 2 studies.
.jpg)
